Finder makes money from featured partners, but editorial opinions are our own.

How to buy Merck-and-Company (MRK) stocks

Learn how to easily invest in Merck-and-Company stocks.

Merck & Company Inc is a drug manufacturers-general business based in the US. Merck-and-Company shares (MRK.US) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $106.34 – a decrease of 0.37% over the previous day. Merck-and-Company employs 67,000 staff and has a market cap (total outstanding shares value) of $270.8 billion.

How to buy shares in Merck-and-Company

  1. Choose a platform. If you're a beginner, our stock-dealing table below can help you choose.
  2. Open your account. Provide your personal information and sign up.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: MRK in this case.
  5. Research stocks. The platform should provide the latest information available.
  6. Buy your stocks. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Best for Beginners

CIBC Investor's Edge


  • Easy to use platform
  • Low fees
  • Student and young investor discounts

Best for Lowest Commissions

Finder Award

Interactive Brokers


  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Best for Easy-to-use App

Questrade


  • $50 in free trades
  • Low commissions
  • Easy-to-use app

Is it a good time to buy Merck-and-Company stock?

Only you can make the decision on the time to leap. The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

Buy Merck-and-Company stocks from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 4 of 4
Name Product Finder Rating Available Asset Types Stock Trading Fee Account Fee Signup Offer Table description
Interactive Brokers
Finder Rating:
★★★★★
4.3 / 5
Stocks, Bonds, Options, ETFs, Currencies, Futures
min $1.00, max 0.5%
$0
N/A
Winner for Best Overall Broker in the Finder Stock Trading Platform Awards.
CIBC Investor's Edge
Finder Rating:
★★★★★
3.8 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs
$4.95–$6.95
$0 if conditions met, or $100
N/A
An easy-to-use platform with access to a variety of tools to help you trade with confidence.
Questrade
Finder Rating:
★★★★★
4.3 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
$4.95 - $9.95
$0
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio to take out some of the guesswork.
CASHBACK
Qtrade Direct Investing
Finder Rating:
★★★★★
3.7 / 5
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get up to $150 cashback. Use promo code OFFER150. Conditions apply. Ends October 31, 2023.
Low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options.
loading

Is Merck-and-Company stock undervalued or overvalued?

Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Merck-and-Company financials

Revenue TTM $58.3 billion
Operating margin TTM 14.87%
Gross profit TTM $42.1 billion
Return on assets TTM 5.12%
Return on equity TTM 7.61%
Profit margin 5.34%
Book value $15.24
Market capitalisation $270.8 billion

TTM: trailing 12 months

Merck-and-Company share dividends

Dividend payout ratio: 103.91% of net profits

Recently Merck-and-Company has paid out, on average, around 103.91% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.72% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 2.72% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $2.84 per share.

Merck-and-Company's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

Merck-and-Company's most recent dividend payout was on 6 October 2023. The latest dividend was paid out to all shareholders who bought their shares by 14 September 2023 (the "ex-dividend date").

Have Merck-and-Company's shares ever split?

Merck-and-Company's shares were split on a 1048:1000 basis on 3 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.

Merck-and-Company overview

Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site